Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKanyılmaz, Gül
dc.contributor.authorEkinci, Özgür
dc.contributor.authorMüge, Akmansu
dc.contributor.authorÇelik, Sevinç
dc.contributor.authorÖztürk, Furkan
dc.date.accessioned2019-05-13T09:04:25Z
dc.date.available2019-05-13T09:04:25Z
dc.date.issued2015
dc.identifier.citationKanyılmaz, G., Ekinci, Ö., Müge, A., Çelik, S., Öztürk, F. (2015). HPV-associated p16 INK4A expression and response to therapy and survival in selected head and neck cancers. Asian Pacific Journal of Cancer Prevention, 16(1), 253-258.en_US
dc.identifier.issn1513-7368
dc.identifier.urihttps://doi.org/10.7314/APJCP.2015.16.1.253
dc.identifier.urihttps://hdl.handle.net/11491/1588
dc.description.abstractBackground: Development of squamous cell cancer of head and neck (SCCHN) is associated with human papillomavirus (HPV) infection, which in turn is closely related with expression of p16 INK4A. Loss of p16 INK4A expression by deletion, mutation, or hypermethylation is common in SCCHN. We here evaluated p16 INK4A as a prognostic marker of treatment response and survival in our SCCHN patients with laryngeal, hypopharyngeal or nasopharyngeal cancers. Materials and Methods: 131 patients diagnosed with SCCHN between January 2,2006 and July 17, 2010 were examined for p16 INK4A. The median age was 60 years (15-82 years). Fifty one patients were stage I-II and 80 were stage III-IV. Immunohistochemical expression of p16 INK4A was analyzed in pretreatment paraffin-embedded tumor blocks. The influence of p16 INK4A status on disease-free survival, and overall survival after treatment was evaluated. Results: P16 INK4A positivity was found in 58 patients (44%). Tumor-positivity for p16INK4A was correlated with improved disease free survival (70.1 months vs 59 months) and improved overall survival (2, 3 and 5-year values; 77% vs 72%, 70% vs 63% and, 63% vs 55%; respectively). On multivariate analysis, stage was determined as independent prognostic factor for disease-free survival. Conclusions: Stage was the major prognostic factor on treatment response and survival in our patients. P16 INK4A status predicts better outcome in laryngeal, hypopharyngeal or nasopharyngeal cancer cases treated with surgery plus adjuvant radiochemotherapy as well as with definitive radiation therapy and/or chemotherapy.en_US
dc.language.isoeng
dc.publisherAsian Pacific Organization for Cancer Preventionen_US
dc.relation.isversionof10.7314/APJCP.2015.16.1.253en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHead and Neck Canceren_US
dc.subjectHPVen_US
dc.subjectOutcomeen_US
dc.subjectP16 INK4aen_US
dc.subjectRadiotherapyen_US
dc.titleHPV-associated p16 INK4A expression and response to therapy and survival in selected head and neck cancersen_US
dc.typearticleen_US
dc.relation.journalAsian Pacific Journal of Cancer Preventionen_US
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.identifier.volume16en_US
dc.identifier.issue1en_US
dc.identifier.startpage253en_US
dc.identifier.endpage258en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster